Angioplasty.Org | Abbott's Absorb Bioresorbable Scaffold Completes Enrollment in 3 Pivotal ... Angioplasty.Org The trials pit the Absorb Bioresorbable Vascular Scaffold against Abbott's flagship everolimus-eluting XIENCE stent in almost 3,000 patients worldwide. The Absorb BVS also elutes everolimus. One of the primary theoretical advantages of this device is ... Abbott Completes Enrollment of Absorb Randomized Clinical Trials in the United ... Abbott Completes Enrollment of Absorb(TM) Randomized Clinical Trials in the ... |
